Shamburg News · 8-K filed Oct 2, 2026, 7:30 AM EDT
Quince Therapeutics Directors Resign Conditionally; Four Directors Appointed Pending Stockholder Approval
IRLA · Quince Therapeutics, Inc.
- Leadership change
- Other event
- Materiality: high
On September 30, 2026, directors June Bray, David Lamond and Christopher Senner tendered conditional resignations from the Board of Quince Therapeutics, Inc., effective two business days after a Special Meeting of Stockholders on October 6, 2026, contingent on stockholder approval of three proposals. The proposals include share issuances tied to Series C Preferred Stock and warrants that may exceed 20% of outstanding common stock and may result in a change of control, and an increase in authorized common stock from 250,000,000 to 275,000,000 shares. On October 1, 2026, the Board approved the conditional appointments of Catherine Bonuccelli, Leone Patterson, James Valentine and Drayton Wise as directors, effective at the same time.
Source: SEC EDGAR, Form 8-K, Item 5.02, accession 0001193125-26-411260.
Written from the filing by Shamburg Markets. Figures are as reported by the company.